"10.1371_journal.pctr.0020027","plos clinical trials","2007-05-25T00:00:00Z","Leigh Peterson; Doug Taylor; Ronald Roddy; Ghiorghis Belai; Pamela Phillips; Kavita Nanda; Robert Grant; Edith Essie Kekawo Clarke; Anderson Sama Doh; Renee Ridzon; Howard S Jaffe; Willard Cates","Family Health International, Durham, North Carolina, United States of America; Duke Clinical Research Institute, Durham, North Carolina, United States of America; University of California San Francisco, San Francisco, California, United States of America; J. David Gladstone Institutes, San Francisco, California, United States of America; Ghana Health Service, Ministry of Health, Accra, Ghana; University of Yaoundé, Yaoundé, Cameroon; Bill and Melinda Gates Foundation, Seattle, Washington, United States of America; Gilead Sciences, Foster City, California, United States of America","LP, RR, RG, HSJ, and WC designed the study. GB was the Clinical Research Manager for this study. LP and PP monitored that the study was conducted per protocol, Good Clinical Practice, and FHI Standard Operating Procedures. EEKC and ASD enrolled patients and collected data or performed experiments for this study. RG helped design a protocol modification, did the resistance testing, interpreted the results, and provided assistance to analyze the data. DT analyzed the data. All authors contributed to writing the paper.","HSJ is an employee and shareholder of Gilead Sciences, which provided tenofovir disoproxil fumarate and matching placebo for the study. RR is with the Bill and Melinda Gates Foundation, which funded the study.","2007","05","Leigh Peterson","LP",12,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
